Navigation Links
New approaches may prevent certain side effects in BRAF mutation-positive melanoma
Date:11/13/2011

SAN FRANCISCO Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

The studies, presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011, further elucidated the potential mechanism of action underlying this skin lesion side effect, which could further the development of next-generation drugs with improved safety and efficacy profiles for the treatment of BRAF mutation-positive melanoma, according to the researchers.

"Our data suggest that adding an epidermal growth factor receptor (EGFR) inhibitor may prevent skin lesions that sometimes appear during treatment with a first-generation BRAF inhibitor," said Gideon Bollag, Ph.D., senior vice president of research at Plexxikon in Berkley, Calif. "Perhaps more importantly, our data also suggest that our next-generation BRAF inhibitors (which we call 'paradox breakers') represent a novel, single-agent treatment that may avoid this side effect and may also extend treatment durability."

In a laboratory study, Bollag and colleagues used skin cells activated by oncogenes such as HRAS or by signaling through the EGFR receptor with a first-generation BRAF inhibitor. They observed that treatment led to upregulation of ligands for the family of HER receptors, consequent skin cell transformation and enhanced growth. In contrast, Plexxikon's novel "paradox breakers" did not induce this upregulation and, therefore, may prevent the skin lesion side effect observed for all first-generation BRAF inhibitors to date.

Bollag said he and his research team were initially surprised by the upregulation of growth factor expression but were able to identify its cause with a model system. They then used this model system to differentiate the new "paradox breaker" compounds.

The "paradox breakers," which are in preclinical development, are being studied in BRAF-mutant cancer, and Plexxikon is aiming to file an investigational new drug application in 2012.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. LIAI launches new division to look at novel approaches to heart disease and inflammation
2. Genetic risk factors may tailor prostate cancer screening approaches
3. Experts discuss challenges in integrative approaches to science
4. MSU project may lead to new approaches against lung cancer
5. Swimming upstream: Molecular approaches to better understand male infertility
6. New paper examines approaches to measuring protein in foods in context of deadly adulterations
7. New approaches to skin cancer prevention
8. 2 in 1: Multi-tasking protein provides new approaches for anti-tuberculosis drugs
9. Project aims to fuse top-down, bottom-up approaches in systems biology
10. BUSM study identifies new potential approaches to treat myelofibrosis
11. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology: